PURPOSE: To evaluate safety and tolerability of cediranib, a highly potent and selective vascular endothelial growth factor signaling inhibitor, in Japanese patients with advanced solid tumors refractory to standard therapies. METHODS: In part A (n = 16), patients received once-daily oral cediranib (10-45 mg) to identify the maximum tolerated dose (MTD). In part B (n = 24), patients with non-small-cell lung cancer or colorectal cancer received multiple daily doses at the MTD. RESULTS: Cediranib 30 mg/day was considered the MTD since 50% of evaluable patients receiving 45 mg/day experienced dose-limiting toxicities in part A (proteinuria and diarrhea n = 1, proteinuria n = 1, thrombocytopenia n = 1). The most common adverse events were diarrhea (n = 34) and hypertension (n = 32). Pharmacokinetic analysis confirmed cediranib as suitable for once-daily oral dosing. Of 32 evaluable patients, two had partial RECIST responses and 24 had stable disease > or =8 weeks. CONCLUSIONS: Cediranib was generally well tolerated at < or =30 mg/day in these Japanese patients and showed encouraging antitumor activity.
PURPOSE: To evaluate safety and tolerability of cediranib, a highly potent and selective vascular endothelial growth factor signaling inhibitor, in Japanese patients with advanced solid tumors refractory to standard therapies. METHODS: In part A (n = 16), patients received once-daily oral cediranib (10-45 mg) to identify the maximum tolerated dose (MTD). In part B (n = 24), patients with non-small-cell lung cancer or colorectal cancer received multiple daily doses at the MTD. RESULTS:Cediranib 30 mg/day was considered the MTD since 50% of evaluable patients receiving 45 mg/day experienced dose-limiting toxicities in part A (proteinuria and diarrhea n = 1, proteinuria n = 1, thrombocytopenia n = 1). The most common adverse events were diarrhea (n = 34) and hypertension (n = 32). Pharmacokinetic analysis confirmed cediranib as suitable for once-daily oral dosing. Of 32 evaluable patients, two had partial RECIST responses and 24 had stable disease > or =8 weeks. CONCLUSIONS:Cediranib was generally well tolerated at < or =30 mg/day in these Japanese patients and showed encouraging antitumor activity.
Authors: David M Hyams; Arlene Chan; Celia de Oliveira; Raymond Snyder; Jeferson Vinholes; M William Audeh; Victor M Alencar; Janine Lombard; Bijoyesh Mookerjee; John Xu; Kathryn Brown; Paula Klein Journal: Invest New Drugs Date: 2013-06-26 Impact factor: 3.850
Authors: Tanja Trarbach; Beate Schultheis; Thomas C Gauler; Vesile Schneider; Dirk Strumberg; Wilfried E E Eberhardt; Stephanie Le Scouiller; Marcelo Marotti; Kathryn H Brown; Joachim Drevs Journal: Invest New Drugs Date: 2011-10-12 Impact factor: 3.850
Authors: Linda L Garland; Kari Chansky; Antoinette J Wozniak; Anne S Tsao; Shirish M Gadgeel; Claire F Verschraegen; Marco A Dasilva; Mary Redman; David R Gandara Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Emily S Robinson; Ursula A Matulonis; Percy Ivy; Suzanne T Berlin; Karin Tyburski; Richard T Penson; Benjamin D Humphreys Journal: Clin J Am Soc Nephrol Date: 2010-01-07 Impact factor: 8.237
Authors: Srikala S Sridhar; Mary J Mackenzie; Sebastien J Hotte; Som D Mukherjee; Ian F Tannock; Nevin Murray; Christian Kollmannsberger; Masoom A Haider; Eric X Chen; Robert Halford; Lisa Wang; S Percy Ivy; Malcolm J Moore Journal: Invest New Drugs Date: 2013-01-26 Impact factor: 3.850